Back to Journals » Neuropsychiatric Disease and Treatment » Volume 13

Productivity and deadweight losses due to relapses of schizophrenia in Japan

Authors Nakamura Y, Mahlich J

Received 26 March 2017

Accepted for publication 13 April 2017

Published 17 May 2017 Volume 2017:13 Pages 1341—1348


Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Miao Sun

Peer reviewer comments 2

Editor who approved publication: Dr Taro Kishi

Yusuke Nakamura,1 Jörg Mahlich1,2

1Health Economics, Janssen Pharmaceutical K.K., Tokyo, Japan; 2Düsseldorf Institute for Competition Economics (DICE), University of Düsseldorf, Düsseldorf, Germany

Background: No study has examined the financial impact of relapses on schizophrenia from the perspective of Japanese society. This study aimed to estimate the societal costs in Japan caused by the relapses of schizophrenia.
Methods: The societal costs in Japan in 2013 due to relapses of schizophrenia were estimated by summing the productivity loss and deadweight loss caused by schizophrenia relapses in 2013. Deterministic sensitivity analysis was conducted for deadweight loss rate, relapse rate, and patient income.
Results: Japan incurred JPY 55,039 million societal costs because of relapses in 2013. This consists of JPY 3,990 million for productivity loss and JPY 51,049 million for deadweight loss. Rate of deadweight loss is the most significant cost driver in the sensitivity analysis.
Conclusion: Relapses of schizophrenia could generate huge amount of societal costs by reducing labor productivity and economic efficiency. To curb these costs, relapse prevention is desired in treating schizophrenia.

Keywords: schizophrenia, relapses, societal costs, productivity loss, deadweight loss, Japan

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]